Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant S-1 plus intermittent paclitaxel after D2 surgery for stage II–III gastric or gastroesophageal junction adenocarcinoma
ChiCTR2500095699Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Relapse-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
tegafurpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500095699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095699.